Dermatol. praxi. 2023;17(2):78-83 | DOI: 10.36290/der.2023.013

Current view on the treatment of nail psoriasis

MUDr. Gabriela Janoušková
Dermatovenerologické oddělení FN Motol, Praha

Psoriasis is a chronic inflammatory immune-mediated disease that affects 2-3% of the population. The prevalence of nail involvement in psoriasis patients ranges from 10 to 82%. Nail psoriasis is considered a risk factor for the development of psoriatic arthritis. It is estimated that 80 to 90% of psoriatic arthritis patients have nail involvement. Although nail manifestations have a serious negative impact on the patient's quality of life, nail psoriasis is often overlooked or ineffectively treated.

Keywords: nail psoriasis, NAPSI, topical and systemic therapy, biologics.

Accepted: June 1, 2023; Published: June 7, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Janoušková G. Current view on the treatment of nail psoriasis. Dermatol. praxi. 2023;17(2):78-83. doi: 10.36290/der.2023.013.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rigopopoulos D, Baran R, Chiheb S, Daniel CR, Di Chiacchio N, et al. Recommendations for the definition, evaluation, and treatment of nail psoariasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus. J Am Acada Dermatol. 2019;81(1):228-240. Go to original source...
    2. Klaasen KMG, van de Kerhof PCM, Pasch MC. Nail psoriasis: a questionnaire- based survey. Br J Dermatol. 2013;169(2): 314-319. Go to original source...
    3. Wilson FC, Icen M, Crowson CS, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoariasis: a population-based study. Arthritis Rheum. 2009;61(2):233-239. Go to original source...
    4. Kaeley GS, Lihi Eder, Aydin SZ, Rich P, Bakewell CJ. Nail psoriasis: diagnosis, assessment, treatment options, and unmet clinical needs. J Rheumatol. 2021;48:1208-1220. Go to original source... Go to PubMed...
    5. Ortonne JP, Baran R, Corvest M, Schmitt C, Voisard JJ, Taieb C. Development and validation of nail psoriasis quality of life scale (NPQ10). J Eur Acad Dermatol Venereol. 2010;24(1):22-27. Go to original source...
    6. Jiaravuthisan MM, Sasseville D, Vender RB, Murény F, Muhn CY. Psoriasis of the nail: anatomy, patology, clinical presentation, and review of the literature on therapy. J Am Acad Dermatol. 2007;57:1-27. Go to original source...
    7. Rich P, Scher RK. Nail Psoriasis Severity Index: A useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49:206-212. Go to original source...
    8. Cassel SE, Bieber JD, Rich P, et al. The modifi end nail psoriasis Severity index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheum. 2007;34:123-129. Go to PubMed...
    9. Wozel G. Psoriasis treatment in diffi cult locations: scalp, nails, and intertriginous areas. Clin Dermatol. 2008;26:448-459. Go to original source... Go to PubMed...
    10. Klaassen KM, Dulak MG, van de Kerkhof PC, Pasch MC. The prevalence of onychomycosis in psoriatic patients: a systematic review. J Eur Acad Dermatol Venereol. 2014;28(5):533-541. Go to original source...
    11. Gregoriou S, Kalogeromitros D, Kosionis N, Gkouvi A, Rigopoulos D. Treatment options for nail psoriasis. Expert Rev Dermatol. 2008;3:339-344. Go to original source...
    12. Baran R, Tosti A. Topical treatment of nail psoriasis with a new corticoid-containing nail lacquer formulation. J Dermatol Treatment. 1999;10(3):201-204. Go to original source...
    13. Nakamura RC, Abreu LD, Duque-Estrada B, Tamler C, Leverone AP. Comparsion of nail lacquer clobetasol effi cacy at 0,05%, 1%, and 8% in nail psoriasis treatment: prospective, controlled and randomized pilot study. An Bras Dermatol Sifi l. 2012;87:203-211. Go to original source... Go to PubMed...
    14. Tzung TY, Chen CY, Yang CY, Lo PY, Chen YH. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol. 2008;88(3):279-280. Go to PubMed...
    15. Rigopoulos D, Gregoriou S, Daniel Iii CR, et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology. 2009;218(4):338-341. Go to original source... Go to PubMed...
    16. Zakeri M, Valikhani M, Mortazavi H, Barzegari M. Topical calcipotriol therapy in nail psoriasis: a study of 24 cases. Dermatol Online J. 2005;11(3):5. Go to original source...
    17. Tosti A, Piraccini BM, Cameli N, et al. Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with bethametasone dipropionate and salicylic acid. Br J Dermatol. 1998;139:655-659. Go to original source...
    18. Balbás GM, Regaña MS, Millet PU. Tacalcitol ointment for the treatment of nail psoriasis. J Dermatol Treat. 2009; 20(5):308-310. Go to original source... Go to PubMed...
    19. Oram Y, Akkaya AD. Treatment of Nail Psoriasis: Common Concepts and New Trends. Dermatol Res Pract. 2013; doi: 10. 1155/2013/180496. Go to original source...
    20. Lin Y-K, See LC, Huang YH, et al. Efficacy and safety of Indigo naturalis extract in oil (Lindiol) in treating nail psoriasis: A randomized, observer-blind, vehicle-controlled trial. Phytomedicine. 2014;21(7):1015-1020. Go to original source... Go to PubMed...
    21. Saricaoglu H, Oz A, Turan H. (2011) Nail psoriasis successfully treated with intralesional methotrexate: case report. Dermatology. 2011;222(1):5-7. Go to original source... Go to PubMed...
    22. Üstüner P, Balevi A, Özdemir M. The Comparison of the Efficacy and Safety of Intralesional Triamcinolone Acetonide and Methotrexate Injections for the Treatment of Fingernail Psoriasis. J Ankara Univ Fac Med. 2018;71:145-151. Go to original source...
    23. Ravindran S, Criton S. Intramatricial injections for nail psoriasis: An open-label comparative study of triamcinolone, methotrexate, and cyclosporine. Indian J Dermatol Venereol Leprol. 2019;85(1):81-82. Go to original source...
    24. Treewittayapoom C, Singvahanont P, Chanprapaph K, Haneke E. The effect of different pulse durations in the treatment of nail psoriasis with 595-nm pulsed dye laser: a randomized, double-blind, intrapatient left-to-right study. J Am Acad Dermatol. 2012;66(5):807-812. Go to original source...
    25. Tosti A, Ricotti C, Romanelli P, Cameli N, Piraccini BM, Evaluation of the Efficacy of acitretin therapy for nail psoriasis. Arch Dermatol. 2009;145(3):269-271. Go to original source... Go to PubMed...
    26. Sánchez-Regaña M, Sola-Ortigosa J, Alsina-Gibert M, et al. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy). J Eur Acad Dermatol Venereol. 2011;25(5):579-586. Go to original source...
    27. Mahmood T, Zaghi D, Menter A. Emerging oral drugs for psoriasis. Expert Opin Emerg Drugs. 2015;20(2):209-220. Go to original source...
    28. Feliciani C, Zampetti A, Forleo P, Cerritelli L, Amerio P, Proietto G, Tulli A, Amerio P. Nail psoriasis: Combined therapy with systemic cyclosporine and topical calcipotriol. J Cutan Med Surg. 2004;8:122-125. Go to original source...
    29. Gümüşel M, Özdemir M, Mevlitoğlu I, Bodur S. Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study. J Eur Acad Dermatol Venereol. 2011;25(9):1080-1084. Go to original source...
    30. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451-485. Go to original source...
    31. Hadeler E, Mosca M, Hong J, Brownstone N, Bhutani T, Liao W. Nail psoriasis: Review of Effective Therapies and Recommendations for Management. Dermatol Ther. 2021;11(3): 799-831. Go to original source...
    32. Elewski BE, Baker CS, Crowley JJ, et al. Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled-trial. J Eur Acad Dermatol Venereol. 2019;33(11):2168-2178. Go to original source...
    33. Ortonne JP, Paul C,Berardesca E, Marino V, Gallo G, Brault Y, Germain JM. A 24-week randomized clinicat trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol. 2013;168(5):1080-1087. Go to original source...
    34. Rich P, Griffiths CEM, Reich K, Nestle FO, Scher RK, Li S, Xu S, Hsu MC, Guzzo C. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol. 2008;58(2):224-231. Go to original source...
    35. Mease P, Husni EM, Charkravarty SD, Kafka S,Parenti D, Kim L, Lo KH, Hsia EC, Kavanaugh A. Evaluation of Improvementin Skin and Nail Psoriasis in Bio-naive Patients with Active Psoriatic Arthritis Treated with Golimumab: Results Through week 52 of the GO-VIBRANTStudy. ACR Open Rheumatol. 2020;2(11):640-647. Go to original source... Go to PubMed...
    36. Mease PJ,Fleischmann R, Deodhar AA, et al. Effect of cetrolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo controlled study (RAPID PsA). An Rheum Dis. 2014;73:48-55. Go to original source...
    37. Foley P, Gordon K, Griffiths CHEM, et al. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions. Jama Dermatol. 2018;154(6):676-683. Go to original source...
    38. Rich P, Bourcier M, Sofen H, Fakharzadeh S, Wasfi Y, Wang Y, Kerkmann U, Ghislain PD, Poulin Y, PHOENIX 1 investigators. Ustekinumab improves nail dinase in patiens with moderate-to-severe psoriasis: results from PHOENIX 1. Br J Dermatol. 2014;170(2):398-407. Go to original source...
    39. Kristensen LE, Keiserman M, Papp K. Efficacy and safety of risankizumab for aktive psoriasis arthritis: 24-week results from the randomised, double- blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022;81:225-231. Go to original source...
    40. Elewski B, Crowley J, Armstrong A, Photowala H, Zhan T, Chen MM, Gooderham M. Efficacy and Safety of Long-term Risankizumab Treatment for Nail, Scalp, and Palmoplantar Psoriasis: A 4.5-Year Interim Analysis From the LIMMitless OpenLabel Extension Trial. Presented at: 31st EADV Congress; Milan, Italy; September 7-10, 2022.
    41. Elewski B, Rich P, Crowley J, Foley P, Wu T, Reyes-servin O, Poulin Y. Risankizumab profile in nail, scalp, and palmoplantar psoriasis: efficacy and safety at 52 weeks in an integrated analysis of patients with moderate-to-severe plaque psoriasis. Presented at: 24th World Congress of Dermatology; Milan, Italy; June 10-15,2019. Accessed August 11, 2021.
    42. Brunasso A. Nail Psoriasis Improvement During Tildrakizumab Therapy: A Real-Life Experience. J Drugs Dermatol. 2022;21(8):914-916. Go to original source... Go to PubMed...
    43. Wasel N, Thaci D, French LE, Conrad C, Dutronc Y, Gallo G, Berggren L, Lacour JP. Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from Phase 3, Head-to-Head Study (IXORA-S). Dermatol Ther (Heidelb). 2020;10(4):663-670. Go to original source... Go to PubMed...
    44. Van de Kerhof P, Guenther L, Gottlieb AB, et al. Ixekizumab treatment improves fingernail psoriasis in patients with moderate to severe psoriasis: results from the randomized, controlled and open- label phases of UNCOVER-3. J Eur Acad Dermatol Venereol. 2017;31(3):477-482. Go to original source...
    45. Elewski B, Rich P, Lain E, Soung J, Lewitt GM, Jacobson A. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results form three phase 3 trials. J Dermatol Treatment. 2020;0(0):1-5. Go to original source...
    46. Reich K, Sullivan J, Arenberger P, Jazayeri S, Mrowietz U, Augustin M, Elewski B, You R, Regnault P, Frueh JA. Secukinumab shows high and sustained efficacy in nail psoriasis: 2,5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol. 2021;184(3):425-436. Go to original source...
    47. Nguyen CM, Leon A, Danesh M, Beroukhim K, Wu JJ, Koo J. Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients with Chronic Psoriasis: Phase 2b and 3, 52-Week, Randomized Placebo-Controlled Trial Results. J Drugs Dermatol. 2016;15(3):272-276. Go to PubMed...
    48. Merola JF, Elewski B, Tatulych S, Lan S, Tallamn A, Kaur M. Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52- week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2017;77(1):79-87. Go to original source...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.